April 21, 2024


Equality opinion

AXSOME DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against Axsome Therapeutics, Inc. and Encourages

NEW YORK–(Enterprise WIRE)–#AXSM–Bragar Eagel & Squire, P.C., a nationally recognized stockholder legal rights law business, reminds traders that a course motion lawsuit has been filed in opposition to Axsome Therapeutics, Inc. (“Axsome” or the “Company”) (NASDAQ: AXSM) in the United States District Court docket for the Southern District of New York on behalf of all individuals and entities who procured or normally acquired Axsome securities amongst December 30, 2019 and April 22, 2022, each dates inclusive (the “Class Period”). Buyers have right up until July 12, 2022 to use to the Court docket to be appointed as guide plaintiff in the lawsuit.

Click on here to participate in the action.

Axsome is a biopharmaceutical enterprise that engages in the development of novel therapies for central anxious program ailments in the United States. The Enterprise is producing, between other solution candidates, AXS-07, a novel, oral, fast absorbed, multi-mechanistic, and investigational medication for the acute procedure of migraine.

Axsome regularly touted AXS-07’s regulatory and industrial prospects in anticipation of the Company’s submission a New Drug Software (“NDA”) to the U.S. Food and Drug Administration (“FDA”) for AXS-07 for the acute remedy of migraine (the “AXS-07 NDA”) based mostly on the drug’s good results in two Period 3 trials. Nonetheless, unbeknownst to traders, the Company’s planning and eventual submission of the AXS-07 NDA was plagued with chemistry, production, and handle (“CMC”) problems.

The grievance alleges that, during the Course Interval, Defendants manufactured materially wrong and misleading statements about the Company’s organization, functions, and prospective customers. Specifically, Defendants designed bogus and/or deceptive statements and/or failed to disclose that: (i) Axsome’s CMC tactics were being deficient with regard to AXS-07 and its manufacturing system (ii) as a end result, Axsome was unlikely to submit the AXS-07 NDA on its initially represented timeline (iii) the foregoing CMC difficulties remained unresolved at the time that the Food and drug administration reviewed the AXS-07 NDA (iv) accordingly, the Fda was not likely to approve the AXS-07 NDA (v) as a outcome of all the foregoing, Axsome had overstated AXS-07’s regulatory and business prospective customers and (vi) as a final result, the Company’s general public statements ended up materially false and misleading at all relevant moments.

On November 5, 2020, Axsome issued a press release reporting the Company’s 3rd quarter 2020 effects. That push release disclosed that the Company “plans to post the [AXS-07] NDA to the Fda in the to start with quarter of 2021, vs . past guidance of the fourth quarter of 2020, to let for inclusion of supplemental manufacturing details to make certain a strong submission bundle.”

On this news, Axsome’s stock price fell $5.22 per share, or 6.99%, to shut at $69.51 for every share on November 5, 2020.

Then, on April 25, 2022, Axsome disclosed in a submitting with the U.S. Securities and Exchange Commission that, “[o]n April 22, 2022, Axsome . . . was educated by the [FDA] that [CMC] issues discovered during the FDA’s critique of the Company’s [NDA] for its AXS-07 item prospect for the acute therapy of migraine are unresolved.” That submitting also disclosed that “[b]ased on the time remaining in the NDA evaluate cycle, the Business expects to acquire a Total Response Letter [(‘CRL’)] with regard to this NDA on or about the Prescription Drug User Fee Act target action date of April 30, 2022.”

On this news, Axsome’s inventory selling price fell $8.60 for every share, or 21.99%, to close at $30.50 for every share on April 25, 2022.

Finally, on May perhaps 2, 2022, Axsome declared that it obtained a CRL from the Fda pertaining to the AXS-07 NDA for the acute therapy of migraine. According to the Company, “[t]he principal causes offered in the CRL relate to [CMC] criteria,” which includes “the need to have for additional CMC facts pertaining to the drug merchandise and producing method.”

If you procured or normally acquired Axsome shares and endured a decline, are a very long-expression stockholder, have info, would like to master additional about these promises, or have any thoughts relating to this announcement or your rights or interests with regard to these issues, remember to get in touch with Brandon Walker or Melissa Fortunato by e-mail at investigations@bespc.com, telephone at (212) 355-4648, or by filling out this get hold of kind. There is no expense or obligation to you.

About Bragar Eagel & Squire, P.C.:

Bragar Eagel & Squire, P.C. is a nationally acknowledged legislation organization with offices in New York, California, and South Carolina. The organization represents personal and institutional investors in professional, securities, derivative, and other advanced litigation in state and federal courts across the country. For far more information and facts about the business, remember to take a look at www.bespc.com. Attorney promotion. Prior outcomes do not warranty related results.


Bragar Eagel & Squire, P.C.

Brandon Walker, Esq.

Melissa Fortunato, Esq.

(212) 355-4648